BACKGROUND AND PURPOSE: Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance. To better understand resistance mechanisms, we examined global kinase activity (kinomic profiling) in both treatment sensitive and resistant human GBM patient-derived xenografts (PDX or "xenolines"). MATERIALS AND METHODS: Thirteen orthotopically-implanted xenolines were examined including 8 with known RT sensitivity/resistance, while 5 TMZ resistant xenolines were generated through serial TMZ treatment in vivo. Tumors were harvested, prepared as total protein lysates, and kinomically analyzed on a PamStation®12 high-throughput microarray platform with subsequent upstream kinase prediction and network modeling. RESULTS: Kinomic profiles indicated elevated tyrosine kinase activity associated with the radiation resistance phenotype, including FAK and FGFR1. Furthermore, network modeling showed VEGFR1/2 and c-Raf hubs could be involved. Analysis of acquired TMZ resistance revealed more kinomic variability among TMZ resistant tumors. Two of the five tumors displayed significantly altered kinase activity in the TMZ resistant xenolines and network modeling indicated PKC, JAK1, PI3K, CDK2, and VEGFR as potential mediators of this resistance. CONCLUSION: GBM xenolines provide a phenotypic model for GBM drug response and resistance that when paired with kinomic profiling identified targetable pathways to inherent (radiation) or acquired (TMZ) resistance.
BACKGROUND AND PURPOSE:Glioblastoma multiforme (GBM) represents the most common and deadly primary brain malignancy, particularly due to temozolomide (TMZ) and radiation (RT) resistance. To better understand resistance mechanisms, we examined global kinase activity (kinomic profiling) in both treatment sensitive and resistant human GBM patient-derived xenografts (PDX or "xenolines"). MATERIALS AND METHODS: Thirteen orthotopically-implanted xenolines were examined including 8 with known RT sensitivity/resistance, while 5 TMZ resistant xenolines were generated through serial TMZ treatment in vivo. Tumors were harvested, prepared as total protein lysates, and kinomically analyzed on a PamStation®12 high-throughput microarray platform with subsequent upstream kinase prediction and network modeling. RESULTS: Kinomic profiles indicated elevated tyrosine kinase activity associated with the radiation resistance phenotype, including FAK and FGFR1. Furthermore, network modeling showed VEGFR1/2 and c-Raf hubs could be involved. Analysis of acquired TMZ resistance revealed more kinomic variability among TMZ resistant tumors. Two of the five tumors displayed significantly altered kinase activity in the TMZ resistant xenolines and network modeling indicated PKC, JAK1, PI3K, CDK2, and VEGFR as potential mediators of this resistance. CONCLUSION: GBM xenolines provide a phenotypic model for GBM drug response and resistance that when paired with kinomic profiling identified targetable pathways to inherent (radiation) or acquired (TMZ) resistance.
Authors: Arend H Sikkema; Sander H Diks; Wilfred F A den Dunnen; Arja ter Elst; Frank J G Scherpen; Eelco W Hoving; Rob Ruijtenbeek; Piet J Boender; Rik de Wijn; Willem A Kamps; Maikel P Peppelenbosch; Eveline S J M de Bont Journal: Cancer Res Date: 2009-06-30 Impact factor: 12.701
Authors: Gaspar J Kitange; Ann C Mladek; Brett L Carlson; Mark A Schroeder; Jenny L Pokorny; Ling Cen; Paul A Decker; Wenting Wu; Gwen A Lomberk; Shiv K Gupta; Raul A Urrutia; Jann N Sarkaria Journal: Clin Cancer Res Date: 2012-06-06 Impact factor: 12.531
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: David T W Jones; Barbara Hutter; Natalie Jäger; Andrey Korshunov; Marcel Kool; Hans-Jörg Warnatz; Thomas Zichner; Sally R Lambert; Marina Ryzhova; Dong Anh Khuong Quang; Adam M Fontebasso; Adrian M Stütz; Sonja Hutter; Marc Zuckermann; Dominik Sturm; Jan Gronych; Bärbel Lasitschka; Sabine Schmidt; Huriye Seker-Cin; Hendrik Witt; Marc Sultan; Meryem Ralser; Paul A Northcott; Volker Hovestadt; Sebastian Bender; Elke Pfaff; Sebastian Stark; Damien Faury; Jeremy Schwartzentruber; Jacek Majewski; Ursula D Weber; Marc Zapatka; Benjamin Raeder; Matthias Schlesner; Catherine L Worth; Cynthia C Bartholomae; Christof von Kalle; Charles D Imbusch; Sylwester Radomski; Chris Lawerenz; Peter van Sluis; Jan Koster; Richard Volckmann; Rogier Versteeg; Hans Lehrach; Camelia Monoranu; Beate Winkler; Andreas Unterberg; Christel Herold-Mende; Till Milde; Andreas E Kulozik; Martin Ebinger; Martin U Schuhmann; Yoon-Jae Cho; Scott L Pomeroy; Andreas von Deimling; Olaf Witt; Michael D Taylor; Stephan Wolf; Matthias A Karajannis; Charles G Eberhart; Wolfram Scheurlen; Martin Hasselblatt; Keith L Ligon; Mark W Kieran; Jan O Korbel; Marie-Laure Yaspo; Benedikt Brors; Jörg Felsberg; Guido Reifenberger; V Peter Collins; Nada Jabado; Roland Eils; Peter Lichter; Stefan M Pfister Journal: Nat Genet Date: 2013-06-30 Impact factor: 38.330
Authors: Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Iana H Haralambieva; Ann L Oberg; Inna G Ovsyannikova; Richard B Kennedy; Diane E Grill; Sumit Middha; Brian M Bot; Vivian W Wang; David I Smith; Robert M Jacobson; Gregory A Poland Journal: PLoS One Date: 2013-05-01 Impact factor: 3.240
Authors: Jinyan Du; Paula Bernasconi; Karl R Clauser; D R Mani; Stephen P Finn; Rameen Beroukhim; Melissa Burns; Bina Julian; Xiao P Peng; Haley Hieronymus; Rebecca L Maglathlin; Timothy A Lewis; Linda M Liau; Phioanh Nghiemphu; Ingo K Mellinghoff; David N Louis; Massimo Loda; Steven A Carr; Andrew L Kung; Todd R Golub Journal: Nat Biotechnol Date: 2008-12-21 Impact factor: 54.908
Authors: Christopher D Willey; Ashley N Gilbert; Joshua C Anderson; George Yancey Gillespie Journal: Semin Radiat Oncol Date: 2015-05-14 Impact factor: 5.934
Authors: Oliver Schnell; Jun Thorsteinsdottir; Daniel Felix Fleischmann; Markus Lenski; Wolfgang Abenhardt; Armin Giese; Jörg-Christian Tonn; Claus Belka; Friedrich Wilhelm Kreth; Maximilian Niyazi Journal: J Neurooncol Date: 2016-09-06 Impact factor: 4.130
Authors: Ashley N Gilbert; Rachael S Shevin; Joshua C Anderson; Catherine P Langford; Nicholas Eustace; G Yancey Gillespie; Raj Singh; Christopher D Willey Journal: J Vis Exp Date: 2016-06-09 Impact factor: 1.355
Authors: Ahmed N Ibrahim; Daisuke Yamashita; Joshua C Anderson; Moaaz Abdelrashid; Amr Alwakeal; Dagoberto Estevez-Ordonez; Svetlana Komarova; James M Markert; Violaine Goidts; Christopher D Willey; Ichiro Nakano Journal: J Neurosurg Date: 2019-10-18 Impact factor: 5.115
Authors: Emeline Brocard; Kristell Oizel; Lisenn Lalier; Claire Pecqueur; François Paris; François M Vallette; Lisa Oliver Journal: Oncotarget Date: 2015-03-30
Authors: Joshua C Anderson; Douglas J Minnich; M Christian Dobelbower; Alexander J Denton; Alex M Dussaq; Ashley N Gilbert; Timothy D Rohrbach; Waleed Arafat; Karim Welaya; James A Bonner; Christopher D Willey Journal: PLoS One Date: 2014-12-30 Impact factor: 3.240
Authors: Helen B Stone; Eric J Bernhard; C Norman Coleman; James Deye; Jacek Capala; James B Mitchell; J Martin Brown Journal: Transl Oncol Date: 2016-02 Impact factor: 4.243